Christian Skorik1,2, Nathaniel K Mullin1,3, Michael Shi1,4, Yosra Zhang1,2, Phoebe Hunter1, Yang Tang1, Brianna Hilton1, Thorsten M Schlaeger1,5,6. 1. Stem Cell Core Facility, Boston Children's Hospital, Stem Cell Program, Boston, Massachusetts. 2. Stemcell Technologies, Cambridge, Massachusetts. 3. Carver College of Medicine, University of Iowa, Iowa City, Iowa. 4. School of Medicine, Case Western Reserve University, Cleveland, Ohio. 5. Harvard Stem Cell Institute, Boston, Massachusetts. 6. Harvard Medical School, Boston, Massachusetts.
Abstract
Translating human induced pluripotent stem cell (hiPSC)-derived cells and tissues into the clinic requires streamlined and reliable production of clinical-grade hiPSCs. This article describes an entirely animal component-free procedure for the reliable derivation of stable hiPSC lines from donor peripheral blood mononuclear cells (PBMCs) using only autologous patient materials and xeno-free reagents. PBMCs are isolated from a whole blood donation, from which a small amount of patient serum is also generated. The PBMCs are then expanded prior to reprogramming in an animal component-free erythroblast growth medium supplemented with autologous patient serum, thereby eliminating the need for animal serum. After expansion, the erythroblasts are reprogrammed using either cGMP-grade Sendai viral particles (CytoTune™ 2.1 kit) or episomally replicating reprogramming plasmids (Epi5™ kit), both commercially available. Expansion of emerging hiPSCs on a recombinant cGMP-grade human laminin substrate is compatible with a number of xeno-free or chemically defined media (some available as cGMP-grade reagents), such as E8, Nutristem, Stemfit, or mTeSR Plus. hiPSC lines derived using this method display expression of expected surface markers and transcription factors, loss of the reprogramming agent-derived nucleic acids, genetic stability, and the ability to robustly differentiate in vitro to multiple lineages.
Translating human induced pluripotent stem cell (hiPSC)-derived cells and tissues into the clinic requires streamlined and reliable production of clinical-grade hiPSCs. This article describes an entirely animal component-free procedure for the reliable derivation of stable hiPSC lines from donor peripheral blood mononuclear cells (PBMCs) using only autologous patient materials and xeno-free reagents. PBMCs are isolated from a whole blood donation, from which a small amount of patient serum is also generated. The PBMCs are then expanded prior to reprogramming in an animal component-free erythroblast growth medium supplemented with autologous patient serum, thereby eliminating the need for animal serum. After expansion, the erythroblasts are reprogrammed using either cGMP-grade Sendai viral particles (CytoTune™ 2.1kit) or episomally replicating reprogramming plasmids (Epi5™ kit), both commercially available. Expansion of emerging hiPSCs on a recombinant cGMP-grade human laminin substrate is compatible with a number of xeno-free or chemically defined media (some available as cGMP-grade reagents), such as E8, Nutristem, Stemfit, or mTeSRPlus. hiPSC lines derived using this method display expression of expected surface markers and transcription factors, loss of the reprogramming agent-derived nucleic acids, genetic stability, and the ability to robustly differentiate in vitro to multiple lineages.
Authors: Insoo Hyun; Olle Lindvall; Lars Ahrlund-Richter; Elena Cattaneo; Marina Cavazzana-Calvo; Giulio Cossu; Michele De Luca; Ira J Fox; Claude Gerstle; Robert A Goldstein; Göran Hermerén; Katherine A High; Hyun Ok Kim; Hin Peng Lee; Ephrat Levy-Lahad; Lingsong Li; Bernard Lo; Daniel R Marshak; Angela McNab; Megan Munsie; Hiromitsu Nakauchi; Mahendra Rao; Heather M Rooke; Carlos Simon Valles; Alok Srivastava; Jeremy Sugarman; Patrick L Taylor; Anna Veiga; Adrianne L Wong; Laurie Zoloth; George Q Daley Journal: Cell Stem Cell Date: 2008-12-04 Impact factor: 24.633
Authors: H K Kleinman; M L McGarvey; J R Hassell; V L Star; F B Cannon; G W Laurie; G R Martin Journal: Biochemistry Date: 1986-01-28 Impact factor: 3.162
Authors: Christoph Bock; Evangelos Kiskinis; Griet Verstappen; Hongcang Gu; Gabriella Boulting; Zachary D Smith; Michael Ziller; Gist F Croft; Mackenzie W Amoroso; Derek H Oakley; Andreas Gnirke; Kevin Eggan; Alexander Meissner Journal: Cell Date: 2011-02-04 Impact factor: 41.582
Authors: Tenneille E Ludwig; Mark E Levenstein; Jeffrey M Jones; W Travis Berggren; Erika R Mitchen; Jennifer L Frane; Leann J Crandall; Christine A Daigh; Kevin R Conard; Marian S Piekarczyk; Rachel A Llanas; James A Thomson Journal: Nat Biotechnol Date: 2006-01-01 Impact factor: 54.908